Literature DB >> 22618954

Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations.

Mirko Pinotti1, Pierpaolo Caruso, Alessandro Canella, Matteo Campioni, Giuseppe Tagariello, Giancarlo Castaman, Sofia Giacomelli, Donata Belvini, Francesco Bernardi.   

Abstract

We investigated the spontaneous ribosome readthrough, virtually unexplored in genes encoding secreted proteins, over coagulation F9 nonsense mutations. Expression of recombinant factor IX (FIX) in eukaryotic cells demonstrated appreciable levels of secreted FIX molecules for the mutations p.R162* (5 ± 0.3% of rFIX-wt antigen levels), p.R294* (3.1 ± 1.1%) and p.R298* (2.5 ± 0.7%), but not for the p.L103*. Western blotting revealed a large proportion of truncated molecules, which correlated with small amounts of full-length FIX (rFIX-162*, ∼0.5%; rFIX-294*; and rFIX-298*, ∼0.2%). Western blotting of plasma from FIX deficient (Hemophilia B) patients revealed traces of full-length FIX for the p.R294* and p.R298* mutations, but not for the p.L103* mutation that triggered major FIX mRNA decay. The detection of full-length proteins has clinical implication, particularly for post-therapeutic immunological complications in Hemophilia. Data in patients' plasma and in vitro, obtained in the proper protein context, support a ribosome readthrough gradient, consistent with its predicted determinants of efficiency.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22618954     DOI: 10.1002/humu.22120

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations.

Authors:  Alessio Branchini; Mattia Ferrarese; Matteo Campioni; Giancarlo Castaman; Rosella Mari; Francesco Bernardi; Mirko Pinotti
Journal:  Blood       Date:  2017-02-14       Impact factor: 22.113

2.  The higher prevalence of missense mutations in hemophilia B compared to hemophilia A could be important in determining a milder clinical phenotype in patients with severe hemophilia B.

Authors:  Daniela Melchiorre; Silvia Linari; Giancarlo Castaman
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

3.  Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B.

Authors:  Claudia Pamela Radic; Liliana Carmen Rossetti; Miguel Martín Abelleyro; Miguel Candela; Raúl Pérez Bianco; Miguel de Tezanos Pinto; Irene Beatriz Larripa; Anne Goodeve; Carlos Daniel De Brasi
Journal:  Thromb Haemost       Date:  2012-10-23       Impact factor: 5.249

Review 4.  Hemophilia B: molecular pathogenesis and mutation analysis.

Authors:  A C Goodeve
Journal:  J Thromb Haemost       Date:  2015-05-18       Impact factor: 5.824

5.  Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity.

Authors:  Alessio Branchini; Matteo Campioni; Maria Gabriella Mazzucconi; Francesca Biondo; Rosella Mari; Maria Patrizia Bicocchi; Francesco Bernardi; Mirko Pinotti
Journal:  FEBS Lett       Date:  2013-08-27       Impact factor: 4.124

6.  A system for coordinated analysis of translational readthrough and nonsense-mediated mRNA decay.

Authors:  Stacey L Baker; J Robert Hogg
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 7.  Hemophilia A and B: molecular and clinical similarities and differences.

Authors:  Giancarlo Castaman; Davide Matino
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

Review 8.  The Molecular Basis of FIX Deficiency in Hemophilia B.

Authors:  Guomin Shen; Meng Gao; Qing Cao; Weikai Li
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

9.  Molecular Basis and Therapeutic Strategies to Rescue Factor IX Variants That Affect Splicing and Protein Function.

Authors:  Mojca Tajnik; Malgorzata Ewa Rogalska; Erica Bussani; Elena Barbon; Dario Balestra; Mirko Pinotti; Franco Pagani
Journal:  PLoS Genet       Date:  2016-05-26       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.